TOLECTIN Drug Patent Profile

When do Tolectin patents expire, and when can generic versions of Tolectin launch?

Tolectin is a drug marketed by Ortho Mcneil Janssen and is included in two NDAs.

The generic ingredient in TOLECTIN is tolmetin sodium. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the tolmetin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tolectin

A generic version of TOLECTIN was approved as tolmetin sodium by RISING on May 27^th, 1993.

Summary for TOLECTIN

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	79
Patent Applications:	4,891
DailyMed Link:	TOLECTIN at DailyMed

US Patents and Regulatory Information for TOLECTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Janssen	TOLECTIN	tolmetin sodium	TABLET;ORAL	017628-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ortho Mcneil Janssen	TOLECTIN 600	tolmetin sodium	TABLET;ORAL	017628-002	Mar 8, 1989		DISCN	Yes	No
Ortho Mcneil Janssen	TOLECTIN DS	tolmetin sodium	CAPSULE;ORAL	018084-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for TOLECTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ortho Mcneil Janssen	TOLECTIN	tolmetin sodium	TABLET;ORAL	017628-001	Approved Prior to Jan 1, 1982

International Patents for TOLECTIN

See the table below for patents covering TOLECTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	416016
Japan	S56426
Japan	S5745428
Japan	S591711

Market Dynamics and Financial Trajectory for TOLECTIN (Tolmetin)

Last updated: March 26, 2026

What is TOLECTIN and its Market Position?

TOLECTIN (tolmetin) is a non-steroidal anti-inflammatory drug (NSAID) used primarily to treat rheumatoid arthritis, osteoarthritis, and other inflammatory conditions. Since its FDA approval in 1981, tolmetin has fallen under the NSAID category alongside drugs such as ibuprofen and naproxen.

Worldwide, NSAID usage remains high, driven by aging populations and increasing prevalence of chronic inflammatory diseases. TOLECTIN's specific market share is modest compared to dominant competitors, with key markets including North America, Europe, and parts of Asia.

How Has the Market Evolved for Tolmetin?

Regulatory Environment and Patent Status

• Patent Expiry: Tolmetin's patent protections expired in the early 2000s. Patent expiration led to generic manufacturing, increasing accessibility but reducing market exclusivity.
• Regulatory Focus: The FDA and EMA continue to scrutinize NSAIDs for safety, particularly gastrointestinal, cardiovascular, and renal risks. This affects prescribing patterns, favoring drugs with better safety profiles.

Competitive Landscape

• Market Share: No recent sales figures for tolmetin are publicly available; it has shifted from being a first-line NSAID to a niche drug.
• Generics and Biosimilars: Multiple generic versions exist, leading to a significant price erosion.
• New NSAIDs and COX-2 Inhibitors: Celecoxib and meloxicam have gained preferences due to improved safety profiles, further diminishing tolmetin’s market share.

Prescribing Trends

• Shift towards NSAIDs with better gastrointestinal safety reduces tolmetin’s prescription volume.
• Increase in awareness of cardiovascular risks associated with NSAIDs influences clinician choices.

What Are the Key Financial Indicators?

Revenue and Sales Data

• No current published revenue for tolmetin from major pharmaceutical companies.
• Market estimates suggest annual global sales of NSAIDs in the billions of dollars, but tolmetin's contribution is negligible and declining.

Cost Dynamics

• Production costs are low due to generic manufacturing. Margins are minimal, and profitability is likely driven more by residual sales than new revenues.
• No recent R&D investments are associated with tolmetin, indicating a mature, off-patent drug niche with no significant pipeline.

Pricing Trends

• Significant price decline post-patent expiry.
• Generic competition caps prices commercially, with retail costs for 200 mg tablets falling below $0.10 per tablet in the US.

What are Future Market Prospects?

Market Growth Potential

• Limited growth prospects due to declining market share and safety concerns.
• Any future sales likely to arise from niche indications, off-label uses, or in regions with limited access to newer NSAIDs.

Regulatory and Safety Impact

• Ongoing safety concerns discourage new off-label use and limit marketing efforts.
• Industry shift favors drugs with better safety profiles; tolmetin faces obsolescence.

Strategic Outlook

• Currently, tolmetin's commercial viability hinges on minimal sales.
• No major pharmaceutical company appears to be prioritizing tolmetin development or repositioning efforts.

How Does the Financial Trajectory Compare to Other NSAIDs?

NSAID	Patent Status	Market Share (Global)	Price Range (per tablet)	Safety Profile
Ibuprofen	Off-patent	High	<$0.05	Well tolerated but causes gastrointestinal issues in high doses
Naproxen	Off-patent	High	~$0.10	Similar safety profile to ibuprofen, with better cardiovascular safety
Celecoxib	Patent (expired in 2014 for most formulations; ongoing patent options in some markets)	Moderate	~$1.00–$2.00	Improved gastrointestinal safety; concerns over cardiovascular risks
Tolmetin	Off-patent	Low	<$0.10	Similar safety concerns to other NSAIDs; less preferred

What Are the Implications for Stakeholders?

• Investors: Little to no future revenue potential; focus on legacy sales or emerging alternatives.
• Manufacturers: Low-margin, highly commoditized market with no significant R&D investments.
• Healthcare Providers: Prescribing behaviors shift toward NSAIDs with better safety profiles.
• Regulators: Continued risk assessments impact sale and use patterns.

Key Takeaways

• Tolmetin's market share has declined since patent expiry due to safety concerns and competition from more favorable NSAIDs.
• No recent revenue figures suggest minimal or no current sales; the drug exists primarily as a generic commodity.
• Prospects for growth are negligible, with future use limited to niche or regional markets.
• Industry trend favors NSAIDs with improved safety profiles, reducing tolmetin’s relevance.

FAQs

1. Is tolmetin still actively marketed?
Most major pharmaceutical companies have ceased active promotion. It remains available as a generic in some regions.

2. Are there any new formulations or developments for tolmetin?
No recent R&D or reformulations are reported. It remains a mature, off-patent drug.

3. How does tolmetin compare to other NSAIDs in safety?
Tolmetin shares similar gastrointestinal and cardiovascular risk profiles with other NSAIDs but is less favored due to limited safety advantages.

4. What is the future outlook for tolmetin’s market?
No significant growth or new indications are expected. It is primarily a legacy drug with declining sales.

5. Would any regulatory changes revitalize tolmetin’s market?
Unlikely, as safety concerns and competitive pressures favor newer NSAIDs with better safety profiles.

---

References

[1] U.S. Food and Drug Administration. (2021). FDA Drug Approvals and Safety Communications.
[2] IMS Health. (2019). NSAID Market Share and Sales Data.
[3] European Medicines Agency. (2020). Safety update on NSAIDs.
[4] Statista. (2022). Global NSAID sales revenue figures.
[5] Prescription drug price databases, 2023.